CIK 0001604464
- Non-accelerated filer
- Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460920988
- Phone
- +1 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- Open-market buys, last 90 days
- $999,994
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$999,994. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-05-15 | Soffer Gad EVP & Chief Strategy Officer | Shares withheld for taxes | −382 | $45.90 | $18K | 266,506 |
| 2018-05-15 | Clark Mitchall G. EVP & Chief R & QA Officer | Option exercise | +4,808 | 138,479 | ||
| 2018-05-15 | Clark Mitchall G. EVP & Chief R & QA Officer | Option exercise · Restricted Stock Units | −4,808 | 0 | ||
| 2018-05-15 | Gallagher Carol Giltner Director | Option exercise | +545 | 111,465 | ||
| 2018-05-15 | Gallagher Carol Giltner Director | Option exercise · Restricted Stock Units | −545 | 0 | ||
| 2018-05-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Option exercise | +25,000 | $11.00 | $275K | 357,905 |
| 2018-05-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −6,885 | $44.44 | $306K | 351,020 |
| 2018-05-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −9,638 | $45.21 | $436K | 341,382 |
| 2018-05-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −9,252 | $46.02 | $426K | 332,130 |
| 2018-05-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Option exercise · Employee Stock Option (Right to Buy) | −25,000 | 25,000 | ||
| 2018-05-14 | Fust Matthew K Director | Sale | −12,286 | $43.57 | $535K | 19,820 |
| 2018-05-10 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $40.08 | $88K | 182,278 |
| 2018-05-10 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $40.98 | $90K | 180,078 |
| 2018-05-09 | Ciechanover Isaac E. Chief Executive Officer | Sale | −1,300 | $38.35 | $50K | 187,578 |
| 2018-05-09 | Ciechanover Isaac E. Chief Executive Officer | Sale | −3,100 | $39.50 | $122K | 184,478 |
| 2018-05-08 | Porter Derrell SVP, Head of Global Commercial | Sale | −1,544 | $40.15 | $62K | 12,500 |
| 2018-05-07 | Berger Dietmar Global Head of R&D | Grant or award | +50,000 | 50,000 | ||
| 2018-05-07 | Berger Dietmar Global Head of R&D | Grant or award · Employee Stock Option (Right to Buy) | +85,000 | 85,000 | ||
| 2018-04-27 | Ciechanover Isaac E. Chief Executive Officer | Sale | −3,900 | $42.63 | $166K | 189,378 |
| 2018-04-27 | Ciechanover Isaac E. Chief Executive Officer | Sale | −500 | $43.95 | $22K | 188,878 |
Page 31 of 44 · 867 trades